Curative Resection of Inoperable, Locally Advanced Gastric Cancer after Neoadjuvant Chemotherapy with Taxotere and Cisplatin.
10.5230/jkgca.2005.5.1.57
- Author:
Han Hong LEE
1
;
Hoon HUR
;
Byung Joo CHAE
;
Wook KIM
;
Hae Myung JEON
Author Information
1. Department of Surgery, St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. hmjeon@catholic.ac.kr
- Publication Type:Case Report
- Keywords:
Advanced stomach cancer;
Neoadjuvant chemotherapy;
Curative resection;
Docetaxel
- MeSH:
Cisplatin*;
Diagnosis;
Drug Therapy*;
Humans;
Induction Chemotherapy;
Microtubules;
Neoplasm Metastasis;
Polymerization;
Polymers;
Stomach Neoplasms*;
Tubulin
- From:Journal of the Korean Gastric Cancer Association
2005;5(1):57-64
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
At diagnosis, the majority of patients with gastric cancer are found to have local invasion or distant organ metastasis, even though the sole measure for a complete cure is a curative resection. A curative resection is hardly applicable for those with invasion and metastasis; thus, trials with neoadjuvant chemotherapy for downstaging the cancer should be considered. Docetaxel is a semisynthetic taxane that promotes tubulin polymerization and inhibits microtubule depolymerization. In recent studies, many metastatic gastric cancers were treated using neoadjuvant chemotherapy with docetaxel, and the response rates were reported. We report here two cases of locally advanced, non-resectable gastric cancer that were candidates for a curative resection after induction chemotherapy with docetaxel and cisplatin.
